Gordon Chau

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Raphael J. Landovitz, Sue Li, Beatriz Grinsztejn et al. · PLoS Medicine · 2018 · 172 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

Raphael J. Landovitz, Sue Li, Joseph J. Eron et al. · The Lancet HIV · 2020 · 171 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

Elizabeth E. Tolley, Sahar Z. Zangeneh, Gordon Chau et al. · AIDS and Behavior · 2020 · 92 citations · Full text

Public Health, Pharmacokinetics, Pharmacology +10

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer et al. · The Lancet Infectious Diseases · 2022 · 81 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084

Susan H. Eshleman, Jessica M. Fogel, Estelle Piwowar‐Manning et al. · The Journal of Infectious Diseases · 2021 · 69 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17